Aviso Financial Inc. Increases Position in Thermo Fisher Scientific Inc. $TMO

Aviso Financial Inc. raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 102,592 shares of the medical research company’s stock after purchasing an additional 7,483 shares during the period. Thermo Fisher Scientific accounts for 2.5% of Aviso Financial Inc.’s investment portfolio, making the stock its 15th largest holding. Aviso Financial Inc.’s holdings in Thermo Fisher Scientific were worth $51,050,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Bernard Wealth Management Corp. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $25,000. Ameriflex Group Inc. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $30,000. Keystone Global Partners LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $31,000. IMA Advisory Services Inc. purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $35,000. Finally, Navigoe LLC purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $37,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on TMO. Royal Bank Of Canada dropped their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 10th. HSBC reiterated a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. UBS Group increased their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research note on Thursday, July 24th. Finally, Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $593.00.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $489.96 on Monday. The firm has a 50 day simple moving average of $434.83 and a 200-day simple moving average of $459.02. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market cap of $185.01 billion, a PE ratio of 28.34, a P/E/G ratio of 2.61 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the company earned $5.37 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 8,000 shares of the stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $454.45, for a total value of $3,635,600.00. Following the completion of the sale, the chief executive officer owned 115,174 shares of the company’s stock, valued at $52,340,824.30. This represents a 6.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,400 shares of company stock valued at $8,345,792 in the last three months. Company insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.